South Carolina Medicaid GLP-1 Coverage 2026: Pattern #26 — Policy-Reversal Termination, 14-Month Coverage Window (Nov 2024–Dec 2025, SHORTEST in 50-State Series), Lowest-Documentation Elimination-Cluster Member, Healthy Blue Formulary Trap, Magellan/Prime Therapeutics sPDL + 5-MCO Architecture

TL;DR — What SC Medicaid Members Need to Know Right Now

South Carolina Medicaid (branded Healthy Connections, administered by the South Carolina Department of Health and Human Services, SCDHHS) does not cover GLP-1 receptor agonists for adult chronic weight management as of January 1, 2026. Coverage was added November 1, 2024 and terminated December 31, 2025 — a window of only 14 months, the shortest-lived Medicaid GLP-1 obesity coverage program documented in this 26-state series.

South Carolina is the fourth and final state in the KFF January 2026 four-state “eliminated coverage” cluster (alongside California, New Hampshire, and Pennsylvania). Within that cluster, SC has the shortest coverage window, the lowest documentary footprint, and is the only state that is simultaneously a member of the elimination cluster AND a non-expansion southern Medicaid state.

The exclusion is anchored at three converging primary sources: (1) the SCDHHS Pharmacy Services Provider Manual (effective January 1, 2026), which lists “Weight control products” as the first categorically non-covered item and separately states “Pharmaceuticals used as anorexiants are excluded from coverage;” (2) the Single Preferred Drug List (sPDL, effective May 1, 2026), which lists in the GLP-1 class only T2D-indicated agents (Ozempic, Trulicity, Victoza, Mounjaro) and omits Wegovy, Saxenda, Zepbound, and Rybelsus entirely; and (3) the November 5, 2025 P&T Committee Meeting Minutes, in which SCDHHS clinical leadership announced the termination effective 12/31/2025.

What is preserved: T2D coverage (Ozempic, Trulicity, Victoza Preferred; Mounjaro Non-Preferred); Wegovy for non-obesity FDA indications (cardiovascular MACE risk reduction and noncirrhotic MASH) per P&T minutes — though no published PA criteria document exists for these pathways. The termination was an SCDHHS Director-level administrative decision, not a state legislative act and not a published Medical Assistance Bulletin equivalent to Pennsylvania's MAB2025112403.

READ THIS FIRST: The Healthy Blue Formulary Trap — a Serious YMYL Risk

Before reading anything else in this article, members enrolled in Healthy Blue of South Carolina (a BlueChoice/Anthem subsidiary) need to understand a critical discrepancy between what Healthy Blue's own formulary says and what South Carolina Medicaid actually covers for chronic weight management.

Healthy Blue's Comprehensive Drug List, effective May 1, 2026, contains a therapeutic class titled “ANTI-OBESITY - GLP-1 RECEPTOR AGONISTS.” Under that class, the formulary shows:

WEGOVY ORAL TABLET — NonCovered/PA Required — PA; QL
WEGOVY SUBCUTANEOUS SOLUTION AUTO-INJECTOR — Covered — PA; QL

A member using Healthy Blue's online formulary search tool and finding the entry “Covered — PA; QL” for Wegovy subcutaneous could reasonably conclude that Wegovy is covered for chronic weight management. That conclusion is wrong.

Here is why the formulary entry does not establish obesity coverage:

1. The SCDHHS Pharmacy Services Provider Manual (effective January 1, 2026) categorically bars “Weight control products” — the first item on the non-covered list — and separately states: “Pharmaceuticals used as anorexiants are excluded from coverage.” This categorical bar applies regardless of any MCO formulary entry.
2. The sPDL (effective May 1, 2026) binds all five MCOs for listed therapeutic classes, and it omits Wegovy, Saxenda, and Zepbound entirely from the GLP-1 class. The sPDL header states verbatim: “All Managed Care plans and traditional Fee For Service utilize this single Preferred Drug List (sPDL) for the therapeutic classes listed below ONLY.” A formulary listing in an MCO's own document cannot override the SCDHHS sPDL exclusion.
3. The “Covered” status for Wegovy subcutaneous reflects the preserved non-obesity FDA indications only — MACE cardiovascular risk reduction and noncirrhotic MASH — per the November 5, 2025 P&T Committee announcement that “Wegovy will continue to be covered for indications other than obesity (e.g., MACE/MASH).” It does NOT reflect chronic weight management coverage.

This Healthy Blue discrepancy is the most serious patient-safety risk in this article. A member who relies on the formulary search and submits a PA request for chronic weight management is facing likely denial — with the added frustration of having relied on their plan's own published document. Healthy Blue's formulary entry has not been updated to reflect the post-January 1, 2026 categorical sPDL exclusion.

This pattern of MCO formulary entries diverging from the categorical exclusion has appeared in other states in this series: Illinois (Meridian/YouthCare), Pennsylvania (January 2026 PDL v8), and now SC. In every case, the state-level PDL exclusion controls. The authoritative documents are the SCDHHS Pharmacy Services Provider Manual and the sPDL, not any MCO formulary.

If you are a Healthy Blue member seeking Wegovy coverage, your MCO member services line (1-855-326-4831) can confirm what indications a PA request can be submitted for. For non-obesity indications (MACE/MASH per FDA labeling), a PA submission citing the FDA-approved indication is the operative pathway — even without a published SC clinical criteria document.

Pattern #26 in the 50-State Series: Lowest-Documentation Policy Reversal in the KFF Four-State Elimination Cluster

South Carolina closes the KFF January 2026 four-state Medicaid GLP-1 obesity-coverage elimination cluster. With this analysis, all four states are documented. SC is the least extensively documented of the four — a “Pennsylvania-direction policy decision with Florida-level documentary footprint.”

South Carolina is also taxonomically unique as the only state in both clusters simultaneously: it is in the KFF four-state “elimination” cluster (CA, NH, PA, SC) AND in the emerging southern non-expansion Medicaid GLP-1 exclusion cluster (AL, FL, GA, SC, TX). Every other elimination-cluster state is either an expansion state (CA, PA, NH) or has a history of coverage before the exclusion. SC is the only state that was a non-expansion state with categorical exclusion architecture that temporarily added and then removed coverage.

The November 5, 2025 P&T Committee Meeting Minutes: What They Actually Say (and What They Do Not)

The canonical primary-source narrative anchor for the South Carolina GLP-1 obesity coverage termination is a single bullet point in the SCDHHS Pharmacy and Therapeutics Committee Meeting Minutes, November 5, 2025. The document is a 5-page PDF whose header (page 1) reads verbatim:

“South Carolina
Department of Health and Human Services
1801 Main Street Columbia, South Carolina 29201-8206
Pharmacy and Therapeutics (P&T) Committee Meeting
November 5, 2025
MINUTES”

Chair Edward Behling, MD called the meeting to order at 4:08 pm. Roll call was taken by Kimberly Bristow, RPh, the Department's Pharmacy Director. SCDHHS staff present included Kevin Wessinger, MD (the senior clinical leader who delivered the GLP-1 termination announcement) and Sarah Hearn-Bailey, Esq. (Department counsel). Prime Therapeutics staff present included Lori Ash, Lisa Correll, PharmD, and Manisa Bulsara, PharmD.

The termination announcement appears under Section IV, “State Updates” (page 1). Verbatim:

“State Updates ……………………………… Kevin Wessinger, MD and Kim Bristow, RPh

• Dr. Wessinger notified committee members that GLP-1 medications for obesity would be removed from the PDL 12/31/2025. There will be no changes to GLP-1 products with respect to the indication for diabetes. Wegovy will continue to be covered for indications other than obesity (e.g., MACE/MASH). If members are currently taking Wegovy for these indications, they may require a new Prior Authorization for those indications.”

Four sentences. That is the totality of the published primary-source record for the South Carolina GLP-1 obesity coverage termination announcement. Contrast with Pennsylvania's MAB2025112403 — a 4-page Medical Assistance Bulletin explicitly invoking federal authority, amending 55 Pa. Code § 1121.54, listing non-obesity carve-out criteria across five pages, and quantifying $112.965 million in state savings — and the difference in documentary footprint is stark.

Critical framing: the committee was informed, not asked. Wessinger's announcement appears under the “State Updates” agenda item — not a P&T action item. There is no associated motion, no committee vote, no new clinical criteria attached to the announcement, and no formal P&T action recorded. The termination was an SCDHHS Director-level administrative decision communicated through the P&T Committee as a courtesy notification. The article must NOT represent the P&T Committee as having “voted to eliminate” GLP-1 obesity coverage.

The August 6, 2025 P&T minutes (the previous quarterly meeting) contain no discussion of GLP-1 obesity coverage. The February 4, 2026 P&T minutes (the first post-termination quarter) contain no reconsideration. This means the administrative decision was made during a 3-month window in fall 2025, with no advance public notice to beneficiaries who had started GLP-1 obesity treatment earlier in 2025. SCDHHS published no public bulletin, memo, or communications-page notice about the termination as of 2026-05-10 — a structural transparency gap that distinguishes SC from every other termination state in the series.

The four sentences also establish the non-obesity-indication preservation: Wegovy for MACE and MASH remains covered for patients with those FDA-approved indications, and existing Wegovy patients on those indications require a new PA submission. However, no published SCDHHS clinical PA criteria document for Wegovy MACE or MASH has been identified as of 2026-05-10 — these pathways exist as P&T minutes prose only.

The Pharmacy Services Provider Manual Categorical Exclusion — the Regulatory-Style Anchor

The SCDHHS Pharmacy Services Provider Manual (effective January 1, 2026) is the binding manual governing Medicaid pharmacy benefits in South Carolina. Its “Non-Covered Services and Definitions” section is the categorical exclusion architecture under which the termination operates.

The document header (page i) reads verbatim:

“PHARMACY SERVICES PROVIDER MANUAL

SOUTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES

PHARMACY SERVICES PROVIDER MANUAL

JANUARY 1, 2026

South Carolina Department of Health and Human Services”

The “Non-Covered Services and Definitions” section (page 16) lists verbatim:

“NON-COVERED SERVICES AND DEFINITIONS

The following is a listing of products excluded from South Carolina Medicaid coverage. These items are considered non-covered, regardless of circumstance:

• Weight control products
• Investigational pharmaceuticals or products.
• Pharmaceuticals determined by the FDA to be less than effective and identical, related or similar drugs (frequently referred to as ‘Drug Efficacy Study Implementation [DESI]’ drugs). …
• Fertility products.
• Pharmaceuticals used for cosmetic purposes or hair growth.
• Cough/Cold medications. …
• Products used to treat sexual or erectile dysfunction.
• Pharmaceuticals related to gender transition are not covered.”

“Weight control products” is the first item on the categorical non-covered list. The phrase “regardless of circumstance” is critical — it means the categorical bar is not subject to medical-necessity override under the manual itself.

The second exclusion anchor appears in Section 5 Utilization Management (page 21), as a Note following the amphetamines PA criteria:

“Note: Pharmaceuticals used as anorexiants are excluded from coverage. Amphetamines for FDA-approved indications for patients from birth to the date of their 21st birthday are routinely covered and do not require PA.”

Together, the “Weight control products” non-covered list entry plus the “anorexiants excluded” Note constitute the SCDHHS regulatory-style anchor. Both track the federal optional-exclusion language at 42 U.S.C. § 1396r-8(d)(2)(A) for “Agents when used for anorexia, weight loss, or weight gain.”

An important historical note: this “anorexiants excluded” language has been in the SC Pharmacy Services Provider Manual since well before November 2024. The November 2024 GLP-1 obesity coverage addition was an exception to this categorical bar — SCDHHS exercised its discretionary authority to add coverage, then exercised the inverse discretion to remove coverage effective January 1, 2026, returning to the categorical-bar default. The bar was never repealed; it was temporarily overridden by administrative action and then restored.

The Pharmacy Services Provider Manual effective January 1, 2026 contains NO provisions specifically addressing: Wegovy MACE risk reduction PA criteria; Wegovy noncirrhotic MASH PA criteria; Zepbound OSA PA criteria; or EPSDT-specific GLP-1 carve-in for under-21 beneficiaries. Patients pursuing non-obesity GLP-1 coverage must rely on direct PA submissions through their MCO citing FDA labeling, with no published SC clinical criteria document to anchor the review.

One additional documentary signal: the prior “GLP-1 Receptor Agonist for Weight Management Criteria” PDF at https://southcarolina.fhsc.com/downloads/provider/SCRx_PAcriteria_weight_mgmt.pdf now returns HTTP 200 with content-length 0 — the URL is functionally retired. Verified 2026-05-10. This URL retirement is a unique documentary signal of the policy change, distinct from any published notice or announcement.

Federal Authority: 42 U.S.C. § 1396r-8(d)(2)(A) — the Discretionary Floor

The federal Medicaid statute provides the legal foundation for states’ ability to exclude weight-loss drug coverage. The relevant provision is 42 U.S.C. § 1396r-8(d)(2), which reads verbatim:

“(d) Limitations on coverage of certain drugs

(2) List of drugs subject to restriction
The following drugs or classes of drugs, or their medical uses, may be excluded from coverage or otherwise restricted:
(A) Agents when used for anorexia, weight loss, or weight gain.
(B) Agents when used to promote fertility.
(C) Agents when used for cosmetic purposes or hair growth.
(D) Agents when used for the symptomatic relief of cough and colds. …”

The operative word is “may” — this is a permissive authority. States are not required to exclude GLP-1 weight-loss coverage; they are permitted to. Tennessee exercised this same discretion to add coverage via TennCare Sequence 10-34-25 (effective January 26, 2026). South Carolina exercised it to add coverage in November 2024 and then to remove coverage effective January 1, 2026.

Unlike Pennsylvania's MAB2025112403, which explicitly cites “See 42 U.S.C. § 1396r-8(d)(2)(A)” by section number in its BACKGROUND/DISCUSSION, the SC P&T minutes, Pharmacy Services Provider Manual, and sPDL do not cite this federal provision by section number. The SC manual's “Pharmaceuticals used as anorexiants are excluded from coverage” language tracks the federal text precisely, but the connection is implicit rather than explicitly asserted. The article treats 42 U.S.C. § 1396r-8(d)(2)(A) as the implicit-but-operative federal authority for SC's exclusion.

It is also worth noting what the federal authority does not do: it does not bar coverage. States exercising the exclusion are making a policy choice. The SCDHHS Director-level administrative decision to terminate was exactly that — a policy choice, not a federal mandate.

The 14-Month Coverage Window: November 2024 Through December 2025

South Carolina added GLP-1 obesity coverage effective November 1, 2024, becoming what KFF Health News described as “the 14th state to cover the drugs for weight loss as well as diabetes.” The eligible drugs under the pre-termination program were Wegovy, Saxenda, and generic liraglutide (Saxenda's FDA-approved obesity-indication molecule).

The pre-termination program's eligibility criteria were among the most stringent in the 26-state series. Per Kenneth Mitchell, MD, bariatric medicine director at Roper St. Francis Healthcare in Charleston (via KFF Health News):

“It’s not just, ‘Send a prescription in and they cover it.’ It’s rather arduous. Not a lot of folks are going to do this.”

The documented eligibility criteria included:

• Adult age (18+)
• BMI qualifying as obese with related health problems
• 6 months of documented nutrition counseling on a 1,200-calorie-per-day diet (documented by Mitchell via KFF Health News reporting)
• Prescriber attestation of increased exercise activity
• 6-month initial PA authorization

Renewal required documented at least 5% body weight loss at the 6-month renewal point, plus continued nutrition counseling participation — per Mitchell's description to KFF Health News. (Note: this renewal criterion is sourced from a prescriber's clinical description, not from a published SCDHHS criteria document.)

SCDHHS projected that only 1,300 beneficiaries out of approximately 1.0 million Healthy Connections enrollees would meet the stringent prerequisites — roughly 0.13% of the program population. SCDHHS spokesperson Jeff Leieritz noted verbatim: “In South Carolina, where more than one-third of all adults, and nearly half of the African American population, qualify as obese, the state Medicaid agency estimates only 1,300 beneficiaries will meet the stringent prerequisites for GLP-1 coverage.”

The actual realized cost of the program: per Leieritz, verbatim:

“Reimbursements for the drugs alone cost $2.3 million in state taxes, plus $5.5 million in federal taxes, for weight loss prescriptions in the last fiscal year.”

$7.8 million total ($2.3M state + $5.5M federal) for weight-loss prescriptions in a partial fiscal year — below the projected $10M annual figure. This stands in contrast to Pennsylvania's fiscal rationale of $112.965 million in state savings (per 55 Pa.B. 8828, December 27, 2025) — SC's cost justification for termination is proportionally thinner.

On the conditional re-add question: Leieritz stated verbatim that “The state Medicaid agency will consider those lower costs when deciding whether to add the medications back onto the state's list of covered drugs in the future.” The “lower costs” reference is to Wegovy's reduced cash-pay list price following manufacturer negotiations. This is a conditional statement, not a commitment. No SC re-add has been announced as of 2026-05-10, and no active SC General Assembly 2025-26 legislation mandating GLP-1 obesity coverage has been identified in primary-source records.

PBM: Magellan Medicaid Administration via the FHSC Portal — Not Acentra, Not OptumRx

South Carolina's Single PDL clinical operations are administered through a contract with Magellan Medicaid Administration / Prime Therapeutics. The operational PA-criteria publishing layer operates through the legacy First Health Services (FHSC) web portal at southcarolina.fhsc.com. This is the portal where SCDHHS publishes the sPDL, P&T minutes, and PA criteria documents referenced throughout this article.

This PBM architecture is distinct from:

• Acentra Health (formerly Kepro) — the PBM for Texas (Pattern #1) and Alabama (Pattern #23) Medicaid programs
• OptumRx — the PBM for Pennsylvania (Pattern #7) and Indiana (Pattern #16)
• MedImpact Healthcare Systems — the PBM for Kentucky (Pattern #21)

The Magellan/Prime Therapeutics arrangement is the clinical and financial analysis support contractor for the SCDHHS P&T Committee, with Prime Therapeutics staff (Lori Ash, Lisa Correll, PharmD, Manisa Bulsara, PharmD) attending P&T meetings as confirmed by the November 5, 2025 minutes. Magellan Medicaid Administration is the legacy brand name; Prime Therapeutics is the parent entity; FHSC (southcarolina.fhsc.com) is the operational web portal.

The sPDL was implemented effective July 1, 2024 as a single-PDL architecture binding all five MCOs and the FFS program for listed therapeutic classes. Prior to July 1, 2024, MCOs could maintain their own formulary preferences. The post-July 2024 sPDL architecture means that any change in the sPDL — including the omission of Wegovy, Saxenda, and Zepbound — applies uniformly across all five MCOs and FFS. There is no MCO-specific coverage variation for sPDL-listed classes.

The only PA document governing GLP-1 injectable coverage as of 2026-05-10 is the “GLP-1 Receptor Agonists and GLP-1/GIP Receptor Agonists Criteria, Revised 05/01/2026” — scoped exclusively to T2D, with Wegovy, Saxenda, and Zepbound absent. The revision history entry of 06/26/2024 notes: “Removed Rybelsus from criteria. Changed title to GLP1 Receptor Agonists” — the document was originally titled to encompass the weight-management agents and was progressively narrowed to T2D-only. The 11/01/2025 revision removed the Clinical Notes section, suggesting an administrative cleanup in the same window as the obesity termination was being decided.

The Five MCOs and the Binding Single-PDL Architecture

South Carolina Medicaid delivers benefits through five risk-bearing Managed Care Organizations and a residual fee-for-service program. All five MCOs are bound by the sPDL for listed therapeutic classes.

1. Absolute Total Care (Centene Corporation) — the MCO with the most operationally transparent GLP-1 termination notice. Member phone: 1-888-404-3727.

Absolute Total Care issued verbatim member-facing notice:

“Starting January 1, 2026, Absolute Total Care will discontinue coverage of GLP-1 drugs Wegovy and Saxenda for the treatment of obesity and for weight loss. If you already have approval for one of these medicines, it will end on December 31, 2025.”

Provider-facing operational timeline:

“Effective January 1, 2026, Absolute Total Care will discontinue coverage of GLP-1 drugs Wegovy and Saxenda for the treatment of obesity.

December 1, 2025: No new approvals or prior authorizations will be issued after December 1, 2025.
December 31, 2025: All existing prior authorizations for these agents will expire.
January 1, 2026: Coverage officially ends for weight loss indications.”

This three-date framework is the canonical MCO operational anchor. Note that Absolute Total Care's notice references only Wegovy and Saxenda — Zepbound is not mentioned. This may reflect the preserved non-obesity Zepbound pathway (OSA), or it may be an oversight. Patients seeking coverage for Zepbound under any indication should submit a direct PA to their MCO citing the specific FDA-approved indication.

2. First Choice by Select Health of South Carolina(AmeriHealth Caritas) — member phone: 1-888-808-0119. Primary-source GLP-1 termination notice not extracted for this article; patients should call member services to confirm coverage posture.

3. Healthy Blue of South Carolina (BlueChoice/Anthem) — member phone: 1-855-326-4831. See the dedicated “Read This First” section above for the Healthy Blue formulary trap. Healthy Blue's formulary lists Wegovy subcutaneous as “Covered — PA; QL” for non-obesity FDA indications only; the categorical sPDL exclusion controls for chronic weight management.

4. Humana Healthy Horizons in South Carolina — member phone: 1-833-589-0427. Primary-source GLP-1 termination notice not extracted for this article; patients should call member services.

5. Molina Healthcare of South Carolina — member phone: 1-888-622-9016. Primary-source GLP-1 termination notice not extracted for this article; patients should call member services.

For First Choice, Humana, and Molina: do not assume their coverage posture mirrors Absolute Total Care's three-date framework. Confirm directly with member services before making any clinical or benefits decision.

What Is Still Covered: GLP-1s for Type 2 Diabetes

The November 5, 2025 P&T announcement was explicit: “There will be no changes to GLP-1 products with respect to the indication for diabetes.” The SC sPDL (May 1, 2026) and the Prime Therapeutics PA criteria document (revised 05/01/2026) both confirm this.

The operative GLP-1 injectable PA criteria for T2D are verbatim from the revised 05/01/2026 document:

“GLP-1 RECEPTOR AGONISTS AND GLP-1/GIP RECEPTOR AGONISTS (INJECTABLES)

Length of Authorization: 6 months (Initial); 1 year (Renewal)

ADULTS CRITERIA – TO APPROVE Trulicity® (dulaglutide), Victoza® (liraglutide), Ozempic® (semaglutide) for Diabetes
• Age ≥ 18 years; AND
• Documented diagnosis of T2DM; AND
• Trial and failure (e.g., A1C goal not met) of intolerance or contraindication to metformin (90-day look back for paid claims in history); AND
• Documentation of baseline A1c within the previous 3 months; AND
• Requested dose does not exceed the maximum FDA-approved dose for the treatment of diabetes mellitus.”

For Non-Preferred agents (liraglutide generic, Mounjaro, Soliqua, Xultophy), the same T2D criteria apply plus: “Must also have a trial or failure of preferred products (Ozempic®, Trulicity®, and Victoza®), or rationale as to why the preferred products cannot be used.”

Renewal requires: initial criteria met + clinical improvement (reduction in A1c from baseline, OR A1c goal achieved, OR improvement in fasting blood glucose) + no treatment-restricting adverse events.

What is NOT covered under the T2D pathway: using Ozempic, Trulicity, or Victoza off-label for weight loss in a patient without T2D. As the SC Daily Gazette noted verbatim: “Ozempic is arguably the most well-known GLP-1 drug and often used off-label for weight loss. But the drug never received federal approval for that use. So, while the state's Medicaid plan pays for Ozempic to treat diabetes, it never covered it for weight loss.”

Rybelsus (oral semaglutide) presents an anomalous case: it has only T2D FDA approval, but was removed from the SC GLP-1 PA criteria document on 06/26/2024 (per the revision history) and does not appear on the May 1, 2026 sPDL. Patients seeking oral semaglutide for T2D in SC Medicaid face a documentary gap.

Appeals: SCDHHS Fair Hearing Pathway and the Administrative Law Court

The SCDHHS Office of Appeals and Hearings administers the fair hearing process for SC Medicaid PA denials. The key procedural parameters (per Disability Rights South Carolina and SCDHHS):

• 30 calendar days from notice of action to file a fair hearing request — send a letter to SCDHHS within this window.
• 10 calendar days from mailed notice to request continued benefits during the appeal (with potential repayment liability if the appeal is lost).
• 90 days from filing to receive a hearing officer decision.
• Appeal from the hearing officer decision to the South Carolina Administrative Law Court (ALC) within 30 days; ALC contact (803) 734-0550; $25 filing fee (waivable for indigency).

A fair hearing can reverse adjudication-error denials — for example, if the MCO misapplied the T2D PA criteria or applied the obesity exclusion to a Wegovy MACE/MASH submission. A fair hearing cannot override a policy-level determination. After January 1, 2026, a GLP-1 obesity coverage appeal faces the categorical Pharmacy Services Provider Manual exclusion — it is theoretically available but structurally constrained.

For non-obesity indications (Wegovy MACE/MASH, Zepbound OSA), a fair hearing appeal has stronger footing: the November 5, 2025 P&T minutes explicitly preserve Wegovy coverage for these indications, and the categorical exclusion does not apply to FDA-approved non-obesity indications. Cite the November 5, 2025 P&T minutes paragraph verbatim in any appeal of a Wegovy MACE or MASH PA denial.

Disability Rights South Carolina (disabilityrightssc.org) is the state's protection-and-advocacy agency that provides free assistance for Medicaid fair hearings. For patients under 21 years old, Disability Rights South Carolina can assess whether the federal EPSDT mandate (42 U.S.C. § 1396d(r)) creates an independently actionable pathway to GLP-1 obesity coverage — though SCDHHS has not published an EPSDT-specific GLP-1 policy parallel to Indiana's BT2023148.

How SC Compares: Pattern #26 vs. PA, FL, CA, NH, and the Southern Non-Expansion Cluster

Vs. Pennsylvania (Pattern #7 — same direction, highest documentation): Both terminated GLP-1 obesity coverage on January 1, 2026. PA had 34 months of coverage vs. SC's 14 months. PA's termination has a 4-page Medical Assistance Bulletin (MAB2025112403) explicitly invoking 42 U.S.C. § 1396r-8(d)(2)(A), amending 55 Pa. Code § 1121.54, and quantifying $112.965 million state savings. SC's termination has a 4-sentence P&T minutes bullet point plus spokesperson quotes. PA published 38-day advance notice to beneficiaries; SC published no advance public notice. SC is “Pennsylvania-direction with Florida-level documentation.”For the full PA comparison, see our Pennsylvania Medicaid GLP-1 coverage 2026 article (Pattern #7).

Vs. Florida (Pattern #4 — documentary footprint analogue): Both are non-expansion southern states. Both operate via operational-silence exclusion patterns (PDL omission + manual categorical bar) rather than explicit published bulletins. FL's exclusion is documented through AHCA PDL absence + GLP-1 criteria PDF silence. SC's is documented through Pharmacy Services Provider Manual categorical exclusion + sPDL omission + P&T minutes + spokesperson quote. SC's documentary footprint is slightly more transparent than FL's because of the P&T minutes paragraph and the Absolute Total Care MCO notice — neither of which has an FL parallel. For the FL comparison, see our Florida Medicaid GLP-1 coverage 2026 article (Pattern #4).

Vs. California (Pattern #2 — reversed-then-restored): Both terminated January 1, 2026. CA subsequently re-added Wegovy for MASH only on April 1, 2026 — a mid-cycle reversal of the reversal. SC's spokesperson left the door open with conditional language about future reconsideration based on lower drug prices, but no SC re-add has been announced. SC and CA are structural inverses on documentation: CA published a Medi-Cal Rx December 12, 2025 advance alert; SC published nothing equivalent.

Vs. North Carolina (Pattern #9 — double reversal): NC terminated October 2025 then reinstated December 2025 within ~60 days. SC is a single termination as of 2026-05-10 with no announced reinstatement. Both states share a low-documentation pattern (actions appear in agency communications, not formal regulatory amendments) but NC reversed quickly while SC has not.

Vs. Alabama (Pattern #23 — same regional cluster): Both non-expansion southern states with categorical pharmacy-manual exclusion language for “Weight control products” / “anorexiants.” Alabama additionally has a Zepbound-OSA PDL footnote and an off-PDL Wegovy MACE Cardiac Agents PA criteria document. SC has neither of these published artifacts — Wegovy non-obesity coverage is asserted in P&T minutes prose only. Alabama and SC share similar structural disease burden but Alabama never had a GLP-1 obesity coverage period to lose.

Regional Context: SC and the Southern Non-Expansion State Cluster

South Carolina is one of 10 non-Medicaid-expansion states as of 2026 (Alabama, Florida, Georgia, Kansas, Mississippi, South Carolina, Tennessee, Texas, Wisconsin, Wyoming). The Healthy Connections eligibility population is concentrated in pregnant women, parents and caretaker relatives at very-low income thresholds, elderly and disabled enrollees, and SSI categorical eligibles. The adult GLP-1 obesity coverage window served roughly 1,300 people — 0.13% of the 1.0 million Healthy Connections population.

The most instructive contrast within the southern non-expansion cluster is Tennessee. TennCare moved affirmatively toward chronic-weight-management coverage in 2025-26: TennCare Sequence 10-34-25, funded by 2025 Public Chapter 530, added the broadest published anti-obesity medication panel in the series effective January 26, 2026 — all 10 traditional AOMs without prior authorization (quantity limits only), plus a single GLP-1 PA form covering five indications simultaneously (T2D, obesity, MACE, OSA, MASH). Tennessee expanded while South Carolina contracted — both states are non-expansion states in Medicaid eligibility terms. This is one of the clearest demonstrations in the 26-state series that non-expansion status does not predict GLP-1 coverage posture.

Brad Wright, a health policy researcher at the University of South Carolina Arnold School of Public Health, explained the structural dynamic to reporters: “You’re seeing states having to make these choices where they have to balance their budget. It could be a real stressor on the budget for sure.” Ada Stewart, a Columbia family physician, observed: “It’s sad that we have medications that could work or could save lives and the individuals who could benefit the most can’t have access to this because of barriers that exist.”

With SC documented, the southern non-expansion GLP-1 exclusion cluster (Alabama, Florida, Georgia, South Carolina, Texas) and the KFF four-state elimination cluster (California, New Hampshire, Pennsylvania, South Carolina) are both fully mapped in this series. SC is the only state in both clusters simultaneously.

What SC Medicaid Members Can Do in 2026

If you are a Healthy Connections member who lost GLP-1 obesity coverage on January 1, 2026, or who is newly seeking GLP-1 coverage, here are the operative pathways:

1. Check Your Non-Obesity Indication First

If you have established cardiovascular disease (documented prior MI, stroke, or symptomatic PAD) and BMI ≥ 27, Wegovy has an FDA-approved MACE risk-reduction indication. If you have noncirrhotic moderate-to-severe MASH (F2-F3 fibrosis), Wegovy has an FDA-approved MASH indication. If you have obstructive sleep apnea with moderate-to-severe AHI, Zepbound has an FDA-approved OSA indication.

Per the November 5, 2025 P&T minutes, SC Medicaid preserves Wegovy coverage for MACE and MASH. Submit a prior authorization request to your MCO citing the FDA-approved indication — not the weight-management indication. Note: no published SC clinical criteria document exists for these pathways; you are submitting against the P&T minutes prose statement. Call your MCO member services to ask what documentation they require.

2. File a Fair Hearing Appeal If Denied

If your non-obesity-indication PA is denied, file a fair hearing request with SCDHHS within 30 calendar days. Cite the November 5, 2025 P&T minutes verbatim: “Wegovy will continue to be covered for indications other than obesity (e.g., MACE/MASH).” Request continued benefits within 10 days of notice. Contact Disability Rights South Carolina (disabilityrightssc.org) for free representation.

3. Explore Commercial Coverage If Eligible

If you become ineligible for Medicaid or have access to an employer plan, many commercial insurers continue to cover GLP-1s for chronic weight management. Open Enrollment periods and special-enrollment qualifying events (including Medicaid loss) provide access to Healthcare.gov plans. For the full commercial coverage landscape, see our GLP-1 insurance coverage across Medicare, Medicaid, and commercial plans.

4. Cash-Pay Options

For patients without viable insurance coverage, cash-pay options have become more accessible since the SC coverage termination. Novo Nordisk has published list prices for Wegovy; LillyDirect offers Zepbound vials at self-pay rates ($299-$449 range, dose-dependent). Foundayo (orforglipron, FDA-approved April 2026) at $149/month cash is the newest option. Saxenda generic (liraglutide 3 mg) is now available from compounding pharmacies, though patients should verify pharmacy legitimacy. For a full review of cost-reduction strategies, see our GLP-1 insurance dropped coverage appeal playbook.

5. Monitor the BALANCE Model and Future SC Policy

CMS Innovation Center launched the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model, which allows state Medicaid agencies to opt in for GLP-1 coverage at favorable pricing beginning May 2026. As of 2026-05-10, no SC announcement of BALANCE participation has been identified. The Leieritz conditional re-add language (“will consider those lower costs”) may reference BALANCE pricing, but this is speculative. Monitor SCDHHS's quarterly P&T Committee meeting schedule (next scheduled meeting: May 6, 2026) for any policy reconsideration.

6. Confirm Current Status Before Any Clinical Decision

Coverage policy is subject to change. Confirm current status with SCDHHS at 1-888-549-0820 or your MCO member services line before making any clinical or benefits decision. Do not rely solely on MCO formulary search tools given the Healthy Blue formulary trap documented above.

See Also

• GLP-1 insurance coverage across Medicare, Medicaid, and commercial plans — the full 26-state taxonomy with SC documented as Pattern #26.
• Pennsylvania Medicaid GLP-1 coverage 2026 (Pattern #7) — the highest-documentation termination state in the KFF cluster; compare SC (same direction, lowest documentation).
• Florida Medicaid GLP-1 coverage 2026 (Pattern #4) — SC's closest documentary footprint analogue among all 26 states; both are silent-operational-exclusion non-expansion southern states.
• California Medi-Cal GLP-1 coverage 2026 (Pattern #2) — both terminated January 1, 2026; CA re-added Wegovy for MASH April 1, 2026; SC has not.
• GLP-1 insurance dropped coverage appeal playbook — four-phase appeal logic and cash-pay bridge strategies; SC is the most recently documented policy-reversal state in this playbook.
• Tennessee Medicaid GLP-1 coverage (Pattern #13) — the structural inverse: TN expanded (Jan 26, 2026) while SC contracted; both are non-expansion southern states.
• Alabama Medicaid GLP-1 coverage (Pattern #23) — southern non-expansion cluster comparison with similar categorical exclusion architecture but with published Zepbound-OSA and Wegovy-MACE PA criteria documents that SC lacks.